Pragmatic Seamless Design for Efficacy Trial of Asthma Management with reduced Cost

Mei Lu, PhD
Christine Joseph, Ph.D

Henry Ford Health System
May 19, 2013
Puff City Pragmatic RCT: Partners

- HFHS Clinical sites
- Kaiser Permanente Georgia
- Center for Health Communication Research
  University of Michigan
- Co-Investigators: Dennis Ownby, MD (consultant/medical advisor)
  Georgia Regents University
  Augusta, GA
  Douglas Roblin, PhD
  Kaiser Permanente Georgia
  Atlanta, GA
  Edward Zoratti, MD
  Henry Ford Health System
Outlines

- Background:
  - The current status of clinical trials
  - Motivation - RFA-- Pilot Studies to Develop and Test Novel, Low-Cost Methods for the Conduct of Clinical Trials
  - Effectiveness of tailored asthma management in urban teens (Puff City)
  - Modifying Puff City for initiation in a clinical setting

- Study design –pragmatic approach
  - RCT parameters (inclusion/exclusion, blinding, randomization, etc)
  - Seamless phase II/III design
  - Data collection
  - Controlling cost

- Study conduct
  - Identifying eligible patients
  - Enrollment process
  - Dissemination

- Status of the trial
Current Status of Clinical Trials

Clinical Trials are critical for medical decision making, however, under the current paradigm…

…only 7% of eligible patients enroll in a clinical trial

…86% of all trials fail to meet enrollment milestones

…study populations of clinical trials often lack diversity or do not represent the targeted population

…the cost of implementation is high (e.g., recruitment and enrollment of participants, follow-up of participants, and data collection) such as using the trial visit instead routine clinical visit; using trial specific data rather than patient’s medical records

…results often cannot be replicated in clinical practice
Motivations

• In 2011, RFA from NHLBI -- Pilot Studies to Develop and Test Novel, Low-Cost Methods for the Conduct of Clinical Trials

• RFA required to test the low-cost methods the trial conduct on a fully developed study treatment or intervention.

• Responded to the RFA with several methods to reduce the trial cost including
  – A seamless adaptive study design and pragmatic approaches
  – Puff City asthma management intervention in urban teens with asthma.
Asthma

DEFINITION
• Airway hyperresponsiveness
• Reversible airway obstruction
• Airway inflammation

TREATMENT
• Clinical Management
  – Assessment of severity
  – Identification of triggers
  – Bronchodilators (Rescue)
  – Anti-inflammatory (Controllers)
• Patient self-regulation
  – Trigger avoidance
  – Assess need for adjusting medication
  – Recognize need for emergency care
  – Partner with health care provider
Average annual number of asthma deaths per 10,000 persons with current asthma, by age and race, National Vital Statistics System, US, 2001–2003

*Centers for Disease Control and Prevention. Surveillance Summaries. MMWR 2007;56.*
Puff City objectives: Improve asthma control

- Motivate teens to adopt positive behaviors
  - Controller medication adherence
  - Having a rescue inhaler nearby
  - Smoking cessation/reduction

- Reduce asthma-related morbidity
  - Acute care visits (emergency department visits)
  - Hospitalizations

- Improve functional status
  - Symptom-days, nights
  - Days of restricted activity
  - School days missed
Tailoring

“...information or change strategies intended to reach one specific person, based on characteristics...unique to that person...and...derived from an individual assessment.

Puff City: The intervention

1. **Log-in**
   - Intro to program
   - Identify behavior status

2. **Summarize risk behaviors**
   - Assess motivation to change
   - No? Benefits of change & compare risk

3. **Select behavior**
   - Identify barriers to behavior change
   - Receive tailored messages

4. **Summarize**
   - Action plan
   - Good-bye message

*Not applicable for students who are "handling their business."*
Puff City Basic: Additional features

Graph 5 of 13

Puff City Flowchart - Session 1 (*for students with 1 or more risks)

NEW Character Intro
Intro:
- What is asthma
- Intro to Puff Man
- Asthma Facts
- We're here/help

NEW Social Support Submodule
If Low Social Support

Questions (Survey B):
- on meds?
- med selection

If High Social Support

Intro: Mot Quests (Survey C)
- Quit smoke?
- Take C Med
- Carry R Med

If high Motivation
Choose Behavior to work on changing (Survey D):
- Quitting smoking
- Taking med daily
- Carrying inhaler
- Nothing

If low motivation
NEW Character Intro
(If not low social support)

NEW Motivation Submodule

if Nothing
Barrier Question (Survey D cont.)

If Unanswered

Scenario questions; Puffman's advice on how to change

Benefits of changing behavior

Referrals
Asthma Counselor (3 potential referrals)

City Tour

Recall

Med selection & device instructions

12/7/07

*Not applicable for students who are "handling their business." Session flows differently*
Puff City intervention framework

Student baseline survey

Theory-based motivating messages to change behavior

1 2 3 4

Tailored Sessions

6 month Follow-up & booster

12 month Follow-up

Outcomes

• Symptom-days
• Symptom-nights
• School days missed
• Emergency department visits
• Hospitalizations
<table>
<thead>
<tr>
<th></th>
<th>aOR</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 2 days/wk/30 days</td>
<td>0.52</td>
<td>0.2-0.8</td>
<td>0.006</td>
</tr>
<tr>
<td>&gt; 3 symptom nights</td>
<td>0.68</td>
<td>0.4-1.0</td>
<td>0.074</td>
</tr>
<tr>
<td>&gt; 2 school days missed</td>
<td>0.7</td>
<td>0.4-1.1</td>
<td>0.090</td>
</tr>
<tr>
<td>&gt; 2 school days missed (asthma)</td>
<td>0.8</td>
<td>0.5-1.5</td>
<td>0.52</td>
</tr>
<tr>
<td>&gt; 4 days of restricted activity</td>
<td>0.5</td>
<td>0.3-0.9</td>
<td>0.010</td>
</tr>
<tr>
<td>&gt; 4 days had to change plans</td>
<td>0.8</td>
<td>0.4-1.7</td>
<td>0.58</td>
</tr>
<tr>
<td>Rebellious</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 2 days/wk/30 days</td>
<td>0.3</td>
<td>0.1 – 0.8</td>
<td>0.016</td>
</tr>
<tr>
<td>&gt; 3 symptom nights</td>
<td>0.3</td>
<td>0.1 – 0.6</td>
<td>0.002</td>
</tr>
<tr>
<td>&gt; 2 school days missed</td>
<td>0.4</td>
<td>0.2 – 0.8</td>
<td>0.007</td>
</tr>
<tr>
<td>&gt; 2 school days missed (asthma)</td>
<td>0.5</td>
<td>0.2 – 1.2</td>
<td>0.12</td>
</tr>
<tr>
<td>&gt; 4 days of restricted activity</td>
<td>0.2</td>
<td>0.1 – 0.5</td>
<td>0.001</td>
</tr>
<tr>
<td>&gt; 4 days had to change plans</td>
<td>0.4</td>
<td>0.1 – 1.1</td>
<td>0.068</td>
</tr>
</tbody>
</table>

*(JAH, 2013)*
Putt City Asthma Management is ready to be disseminated into different settings such as at the clinic.
Designing a Cost-effective Efficacy Trial in a “Real World” Setting

• Seamless Adaptive Design
  – Phase II/III trial

• Pragmatic Approaches
  – Trial should reflect routine practice and patient selection criteria should be broad
  – Controls should be standard care vs. placebo
  – Outcomes should include broad measures of health-related quality of life from the patient’s point of view
Why Seamless Adaptive Design?

Combines the traditional II and III phases and includes patients enrolled before, and after, adaptation in the final analysis for intervention efficacy.

Advantage
- A reduction of the required sample size and study duration,
- A time and cost saving: the trial my stop early at Phase II when
  - there are toxicity concerns,
  - there is no evidence of drug activity (i.e., futility analysis)
  - a drug has a dramatic effect leading to early termination due to a high certainty of efficacy.

Limitation- requires a well-understood efficacy endpoint
Seamless Adaptive Phase II/III Trial for Asthma Management

250 patients: 125/group all asthma

Arm 1: Tailored online education
Arm 2: Generic online education

Phase II

Phase III

1st look

2nd look

After Phase II

Moderate-severe asthma
104 Patients

Notices, the award only supports up to Phase II Component of the trial
Study Population: inclusion/exclusion criteria

Inclusion criteria
- Using modified HEDIS protocol (denominator) to identify teens with “persistent” asthma using EMR
  - Teens aged 13-19 years who meet at least 1 of the following criteria
    - > 1 Emergency Department visit with asthma as principal diagnosis
    - > 1 acute inpatient claim/encounter with asthma as principal diagnosis
    - > 4 outpatient visits on different dates of service with asthma listed as one of the diagnoses and at least 2 asthma medication dispensing events
    - > 4 asthma medication dispensing events

Exclusion criteria
- Patient does not meet eligibility criteria for asthma,
- Not proficient in English (Puff City is currently only available in English)*
- Patient or caregiver is unable to complete assent/consent even with help; and
- patients have been previously enrolled in Puff City trials.

*To accommodate caregivers with limited English proficiency, consent forms will be available in Spanish and Arabic.
Puff City Phase II/III Trial: Study Design

- Generate letter
- Puff City
- Computer-tailored sessions
- Control

1st 2nd 3rd 4th

Generic asthma education sessions

Follow-up assessments

- 6 mo visit
- 12 mo visit

Asthma Control Test
Asthma exacerbations

Randomization

Puff City 1st 2nd 3rd 4th

Computer-tailored sessions

Obtain baseline Outcomes

Option for online consent available

Clinic visit

Confirm/Obtain assent/consent

Baseline Session

Medical Record Abstraction & patient’s self-report
Pragmatic Approach and Cost Reduction

1. Minimize visits designed solely for the purpose of retrieving trial measurements (1, 2, 3, 4)
2. Minimize specialized infrastructure developed solely for conduct of the clinical trial (1-4, 5, 6, 7, 8)
3. Explore novel methods of obtaining patient consent, minimizing need for specialized staff …while still meeting ethical/legal requirements. (9)
4. Employ low-cost methods of monitoring study conduct such as adherence (10, 11)

- Scan appt system: ID potential participants
- EMR: Determine eligibility
- Notify clinic

Option for online consent available

Clinic visit
- Confirm/OBTAIN assent/consent
- Baseline Session
- Obtain baseline Asthma Control Test

Generate letter

Control
- 1st 2nd 3rd 4th

Generic asthma education sessions

Puff City
- 1st 2nd 3rd 4th

Computer-tailored sessions

Asthma Control Test
Asthma exacerbations

Follow-up surveys
- 6 mo visit
- 12 mo visit

Medical Record Abstraction

Explore novel methods of obtaining patient consent, minimizing need for specialized staff …while still meeting ethical/legal requirements. (9)
CRF Data Collection Processes

- CRF Data Collection At sites
- Medical Abstracting CRF
- Participants
- Pt self-report /survey
- PCs Information
- Tracking database SQL-sever
- Data discrepancies
- HFHS DCC Databases (OC, EMR)
- PC Web/Data Warehouse (online CRF only)
- Transferring daily

IRB Approved Protocol
Pragmatic Approach: Data Collection

- Eligibility form (OC)

- Baseline
  - Teen baseline (on PC web)
  - Asthma medicine (OC)

- Session surveys (participant on UM web)

- Follow-up
  - Participant 6 and 12 month FU (on PC web)
  - Caregiver 12 month survey (OC chart Review/Telephone)
  - Adverse Event data collection (OC)

- EMR data in VDW structure formats – Both HFHS and KPGA have VDW EMR data
EMR data: Demographic, pharmacy; Census; Encounter data
Endpoints at year 1 and Analyses:

- Primary (P1) ACT (0-19)
- Secondary:
  - S1: Asthma exacerbations
  - S2: self-report of symptom-days,
  - S3: symptom-nights,
  - S4: days of restricted activity, and
  - S5: school/work days missed.
  - S6: ED visits and hospitalization
- Exploratory:
  - E1: the cost;
  - E2: cost effectiveness of Puff City
  - E3: reliability of EMR data collection
Interim Analyses and DSMB

- Planning to have 2 DSMB meetings /conference calls when 40% and 70% (the end of Phase II component) of patients complete 1 year endpoints

- DSMB agenda items:
  1) Recruitment and retention
  2) Patient safety
  3) Protocol deviation
  4) Study endpoints

- Seek DSMB recommendation to stop or continue the trial
Assuming effect size of 0.3 (0.33 - 0.54), two-sided test, 354 subjects in total, 2 interim unequal looks when 40% and 70% (250 for Phase II component of the trial) of patients have complete year 1 follow-up, we will have 80% power to detect a significant intervention effect if test statistic or p-value is ± 3.3569 or 0.0008 at 1st look, ± 2.4341 or 0.0149 at 2nd look or ± 2.0017 or 0.0453 at the final analysis.
Thank You

Questions?